26.71

0.45% 0.12

After Hours: 26.71

Arcutis Biotherapeutics Inc (ARQT)

Overview News Price History Option Chain Financials Why ARQT Down? Discussions Forecast

Arcutis Biotherapeutics Inc stock is traded at $26.71, with a volume of 1.10M. It is up +0.45% in the last 24 hours and down -0.26% over the past month. Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Previous Close:

$26.59

Open:

$26.68

24h Volume:

1.10M

Relative Volume:

0.61

Market Cap:

$3.27B

Revenue:

$317.93M

Net Income/Loss:

$-44.32M

P/E Ratio:

-75.35

EPS:

-0.3545

Net Cash Flow:

$-48.24M

1W Performance:

+2.45%

1M Performance:

-0.26%

6M Performance:

+81.21%

1Y Performance:

+102.20%

1-Day Range:

$25.89

$26.76

1-Week Range:

$25.84

$27.62

52-Week Range:

$11.55

$31.77

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Name

Arcutis Biotherapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

805-418-5006

Address

3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA

Employee

342

Twitter

@ArcutisBio

Next Earnings Date

2024-12-06

Latest SEC Filings

ARQT's Discussions on Twitter

Compare ARQT vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARQT Arcutis Biotherapeutics Inc	26.71	3.26B	317.93M	-44.32M	-48.24M	-0.3545
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-25-25	Initiated	Goldman	Neutral
Dec-30-24	Initiated	H.C. Wainwright	Buy
Aug-28-24	Initiated	Jefferies	Buy
Jan-03-24	Upgrade	Mizuho	Neutral → Buy
Oct-26-23	Downgrade	Mizuho	Buy → Neutral
Oct-13-23	Downgrade	Goldman	Buy → Neutral
Sep-07-22	Initiated	Needham	Buy
Mar-17-22	Initiated	Goldman	Buy
Jun-30-21	Initiated	Mizuho	Buy
May-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-09-20	Upgrade	Goldman	Neutral → Buy
Oct-08-20	Initiated	Truist	Buy
Feb-25-20	Initiated	Cantor Fitzgerald	Overweight
Feb-25-20	Initiated	Cowen	Outperform
Feb-25-20	Initiated	Goldman	Neutral
Feb-25-20	Initiated	Guggenheim	Buy

View All

Arcutis Biotherapeutics Inc Stock (ARQT) Latest News

Feb 11, 2026

Arcutis at Guggenheim Summit: Strategic Growth and Market Expansion By Investing.com - Investing.com Canada

Feb 11, 2026

Arcutis Biotherapeutics Touts ZORYVE Expansion, New Indications and 2026 Cash-Flow Breakeven Goal - MarketBeat

Feb 11, 2026

Have Insiders Sold Arcutis Biotherapeutics Shares Recently? - simplywall.st

Feb 11, 2026

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Shows High-Growth Momentum and Strong Technical Setup - ChartMill

Feb 11, 2026